The use of low molecular weight heparin–pluronic nanogels to impede liver fibrosis by inhibition the TGF-β/Smad signaling pathway

Latella, 2009, Targeted disruption of Smad 3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice, Liver Int, 29, 997, 10.1111/j.1478-3231.2009.02011.x Hu, 2009, Adenovirus-mediated transfer of siRNA against PAI-1 mRNA ameliorates hepatic fibrosis in rats, J Hepatol, 51, 102, 10.1016/j.jhep.2009.02.025 Du, 2007, Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats, J Pharmacol Exp Ther, 322, 560, 10.1124/jpet.107.122481 Iredale, 2007, Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ, J Clin Invest, 117, 539, 10.1172/JCI30542 Friedman, 2003, Liver fibrosis – from bench to bedside, J Hepatol, 38, S38, 10.1016/S0168-8278(02)00429-4 Bataller, 2005, Liver fibrosis, J Clin Invest, 115, 209, 10.1172/JCI24282 Pinzani, 2001, Cytokine receptors and signaling in hepatic stellate cells, Semin Liver Dis, 21, 397, 10.1055/s-2001-17554 Lotersztajn, 2005, Hepatic fibrosis: molecular mechanisms and drug targets, Annu Rev Pharmacol Toxicol, 45, 605, 10.1146/annurev.pharmtox.45.120403.095906 Parsons, 2007, Molecular mechanisms of hepatic fibrogenesis, J Gastroenterol Hepatol, 22, S79, 10.1111/j.1440-1746.2006.04659.x Yang, 1999, Targeted disruption of SMAD 3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta, EMBO J, 18, 1280, 10.1093/emboj/18.5.1280 Xavier, 2004, Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone, J Biol Chem, 279, 15167, 10.1074/jbc.M309798200 Hirsh, 2004, Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy, Chest, 126, 188S, 10.1378/chest.126.3_suppl.188S Quader, 1998, Low molecular weight heparins: current use and indications, J Am Coll Surg, 187, 641, 10.1016/S1072-7515(98)00255-5 Norrby, 2006, Low-molecular-weight heparins and angiogenesis, APMIS, 114, 79, 10.1111/j.1600-0463.2006.apm_235.x Frizelle, 1992, Evaluation of the effects of low molecular weight heparin on inflammation and collagen deposition in chronic coxsackievirus B3-induced myocarditis in A/J mice, Am J Pathol, 141, 203 Shi, 2003, Effects of heparin on liver fibrosis in patients with chronic hepatitis B, World J Gastroenterol, 9, 1611, 10.3748/wjg.v9.i7.1611 Abdel-Salam, 2005, A study of unfractionated and low molecular weight heparins in a model of cholestatic liver injury in the rat, Pharmacol Res, 51, 59, 10.1016/j.phrs.2004.04.009 Li, 2006, Long-term administering low anticoagulant activity heparin can lessen rat hepatic fibrosis induced by either CCl(4) or porcine serum injection, Hepatol Res, 36, 115, 10.1016/j.hepres.2006.07.004 Douketis, 1996, The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study, Thromb Haemost, 75, 254, 10.1055/s-0038-1650255 Park, 2008, Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth, Pharm Res, 25, 2786, 10.1007/s11095-008-9643-y Lee, 2006, Efficacy of orally active chemical conjugate of low molecular weight heparin and deoxycholic acid in rats, mice and monkeys, J Control Release, 111, 290, 10.1016/j.jconrel.2005.12.011 Kim, 2007, Absorption study of deoxycholic acid-heparin conjugate as a new form of oral anti-coagulant, J Control Release, 120, 4, 10.1016/j.jconrel.2007.03.008 Lee, 2009, Polyproline-type helical-structured low-molecular weight heparin (LMWH)–taurocholate conjugate as a new angiogenesis inhibitor, Int J Cancer, 124, 2755, 10.1002/ijc.24239 Khattak, 2005, Pluronic F127 as a cell encapsulation material: utilization of membrane-stabilizing agents, Tissue Eng, 11, 974, 10.1089/ten.2005.11.974 Park, 2008, Nanoaggregate of thermosensitive chitosan–pluronic for sustained release of hydrophobic drug, Colloids Surf B Biointerfaces, 63, 1, 10.1016/j.colsurfb.2007.10.024 Tsukamoto, 1990, Experimental models of hepatic fibrosis: a review, Semin Liver Dis, 10, 56, 10.1055/s-2008-1040457 Lee, 2001, Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent, Circulation, 104, 3116, 10.1161/hc5001.100627 Ikejima, 2002, Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat, Gastroenterology, 122, 1399, 10.1053/gast.2002.32995 Jamall, 1981, A simple method to determine nanogram levels of 4-hydroxyproline in biological tissues, Anal Biochem, 112, 70, 10.1016/0003-2697(81)90261-X Seifert, 1995, Beta-carotene (provitamin A) decreases the severity of CCl4-induced hepatic inflammation and fibrosis in rats, Liver, 15, 1, 10.1111/j.1600-0676.1995.tb00098.x Smith, 1985, Measurement of protein using bicinchoninic acid, Anal Biochem, 150, 76, 10.1016/0003-2697(85)90442-7 Benyon, 1996, Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver, Gastroenterology, 110, 821, 10.1053/gast.1996.v110.pm8608892 Preaux, 1999, Matrix metalloproteinase-2 activation in human hepatic fibrosis regulation by cell-matrix interactions, Hepatology, 30, 944, 10.1002/hep.510300432 Benyon, 2001, Extracellular matrix degradation and the role of hepatic stellate cells, Semin Liver Dis, 21, 373, 10.1055/s-2001-17552 Hemmann, 2007, Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies, J Hepatol, 46, 955, 10.1016/j.jhep.2007.02.003 Liu, 2009, The preventive effects of heparin-superoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice, Mol Cell Biochem, 327, 219, 10.1007/s11010-009-0060-2 Iredale, 1995, Tissue inhibitor of metalloproteinase-I and interstitial collagenase expression in autoimmune chronic active hepatitis and activated human hepatic lipocytes, Clin Sci (Lond), 89, 75, 10.1042/cs0890075 Knittel, 1999, Expression patterns of matrix metalloproteinases and their inhibitors in parenchymal and non-parenchymal cells of rat liver: regulation by TNF-alpha and TGF-beta1, J Hepatol, 30, 48, 10.1016/S0168-8278(99)80007-5 Iredale, 1992, Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver, J Clin Invest, 90, 282, 10.1172/JCI115850 Herbst, 1997, Tissue inhibitor of metalloproteinase-1 and -2 RNA expression in rat and human liver fibrosis, Am J Pathol, 150, 1647 Iredale, 1996, Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis, Hepatology, 24, 176, 10.1002/hep.510240129 Iredale, 1998, Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors, J Clin Invest, 102, 538, 10.1172/JCI1018 Knittel, 2000, Expression of matrix metalloproteinases and their inhibitors during hepatic tissue repair in the rat, Histochem Cell Biol, 113, 443, 10.1007/s004180000150 Yoshiji, 2002, Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor, Tumour Biol, 23, 348, 10.1159/000069792 Corpechot, 2002, Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis, Hepatology, 35, 1010, 10.1053/jhep.2002.32524 Ankoma-Sey, 2000, Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells, Hepatology, 31, 141, 10.1002/hep.510310122 Prosser, 2006, Molecular therapy for hepatic injury and fibrosis: where are we?, World J Gastroenterol, 12, 509, 10.3748/wjg.v12.i4.509